Debiopharm Group Initiates Debio 0932 Phase I Trial
Debiopharm Group said that the trial will evaluate the maximum tolerated dose and safety of Debio 0932 in patients suffering from advanced solid tumours or lymphoma. Debio 0932
Evogene and ELEO have entered a scientific collaboration aimed at discovering and developing new oral small-molecule inhibitors targeting the Proprotein convertase subtilisin/kexin type 9 (PCSK9) pathway for hyperlipidemia and cardiovascular diseases.
The collaborative program is expected to encompass training for Johns Hopkins researchers in the NYSCF laboratory in Manhattan, specific research collaborations and a NYSCF fellowship to support Johns